Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats
The present study examined the effects of the selective 5‐HT6 receptor antagonist 4‐amino‐N‐(2, 6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide (Ro 04–6790) on locomotor activity and unconditioned behaviour in male Sprague Dawley rats (230–300 g). In non‐quantified behavioural observations, a...
Gespeichert in:
| Veröffentlicht in: | British journal of pharmacology 1999-04, Vol.126 (7), p.1537-1542 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1542 |
|---|---|
| container_issue | 7 |
| container_start_page | 1537 |
| container_title | British journal of pharmacology |
| container_volume | 126 |
| creator | Bentley, Jane C Bourson, Anne Boess, Frank G Fone, Kevin C F Marsden, Charles A Petit, Nadine Sleight, Andrew J |
| description | The present study examined the effects of the selective 5‐HT6 receptor antagonist 4‐amino‐N‐(2, 6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide (Ro 04–6790) on locomotor activity and unconditioned behaviour in male Sprague Dawley rats (230–300 g).
In non‐quantified behavioural observations, animals treated with Ro 04–6790 (3, 10 or 30 mg kg−1, i.p) showed no overt behavioural signs except a dose‐dependent reduction in locomotor activity and a behavioural syndrome of stretching, yawning and chewing. The latter behaviour was most pronounced between 30 and 90 min following the administration of Ro 04–6790.
Detailed analysis of the stretching and yawning behaviour showed that Ro 04–6790 (3, 10 or 30 mg kg−1, i.p.) dose‐dependently induced stretching. The number of stretches observed following treatment with either Ro 04–6790 (10 mg kg−1 i.p.) or Ro‐04‐6790 (30 mg kg−1, i.p.) was significantly greater than that observed in saline‐treated rats. The yawning behaviour, however, was not dose‐dependent nor was the number of yawns in any of the drug treated groups significantly greater than in those treated with saline.
Pretreatment (30 min) with the non‐selective muscarinic antagonists scopolamine (0.1, 0.3 or 1 mg kg−1, i.p.) and atropine (0.3, 1 or 3 mg kg−1, s.c.) but not methylatropine (1, 3 or 10 mg kg−1, s.c) significantly inhibited stretching induced by Ro 04–6790 (30 mg kg−1, i.p.).
The dopamine D2‐like receptor antagonist, haloperidol (0.03, 0.1 or 0.3 mg kg−1, s.c.) given at the same time as Ro 04–6790 (30 mg kg−1, i.p.) had no effect on the stretching induced by the 5‐HT6 antagonist.
These data suggest that systemic injection of the 5‐HT6 antagonist, Ro 04–6790, produces a stretching behaviour that appears to be mediated by an increase in cholinergic neurotransmission in the CNS and which could be a useful functional correlate for 5‐HT6 receptor blockade. There is no evidence for dopamine D2‐like receptor involvement in this behaviour.
British Journal of Pharmacology (1999) 126, 1537–1542; doi:10.1038/sj.bjp.0702445 |
| doi_str_mv | 10.1038/sj.bjp.0702445 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1565929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69744070</sourcerecordid><originalsourceid>FETCH-LOGICAL-p3753-1106d7c431234ed6f81a29d02cbb91871c53cfeca9f747560c1cd302ad43ecf3</originalsourceid><addsrcrecordid>eNpVkcFOGzEQhq2KqqS01x4rHxAnEuy1vd69IBVUGiQkqip3y-udTRxt7MX2psqNR0DiDXkSXJG2cJrDfPPN6B-EvlAyo4RVZ3E9a9bDjEhScC7eoQnlspwKVtEDNCGEyCmlVXWIPsa4JiQ3pfiADvNowUTFJ-ju2m0hJrvUyXqHfYdjCpDMyrolbmClt9aPAVvXjgZa3OxwWgGO0INJdgtYPN0_zBclDmBgSD5g7ZJeemdjOsW_PCb86f6xlDU5zQ4cdIqf0PtO9xE-7-sRWlx9X1zOpze3P64vv91MByYFy2eTspWGM1owDm3ZVVQXdUsK0zQ1rSQ1gpkOjK47yaUoiaGmZaTQLWdgOnaEzl-0w9hsoDXgUtC9GoLd6LBTXlv1tuPsSi39VlFRirqos-BkLwj-bswZqY2NBvpeO_BjVGUtOc-5Z_Dr603_VvwNOQPHe0BHo_suaGds_M9JkVUyY-wF-2172L3S_DFVKq5V_rTaf1pd_JxTIhl7BkFdnsI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69744070</pqid></control><display><type>article</type><title>Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats</title><source>MEDLINE</source><source>Wiley Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Bentley, Jane C ; Bourson, Anne ; Boess, Frank G ; Fone, Kevin C F ; Marsden, Charles A ; Petit, Nadine ; Sleight, Andrew J</creator><creatorcontrib>Bentley, Jane C ; Bourson, Anne ; Boess, Frank G ; Fone, Kevin C F ; Marsden, Charles A ; Petit, Nadine ; Sleight, Andrew J</creatorcontrib><description>The present study examined the effects of the selective 5‐HT6 receptor antagonist 4‐amino‐N‐(2, 6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide (Ro 04–6790) on locomotor activity and unconditioned behaviour in male Sprague Dawley rats (230–300 g).
In non‐quantified behavioural observations, animals treated with Ro 04–6790 (3, 10 or 30 mg kg−1, i.p) showed no overt behavioural signs except a dose‐dependent reduction in locomotor activity and a behavioural syndrome of stretching, yawning and chewing. The latter behaviour was most pronounced between 30 and 90 min following the administration of Ro 04–6790.
Detailed analysis of the stretching and yawning behaviour showed that Ro 04–6790 (3, 10 or 30 mg kg−1, i.p.) dose‐dependently induced stretching. The number of stretches observed following treatment with either Ro 04–6790 (10 mg kg−1 i.p.) or Ro‐04‐6790 (30 mg kg−1, i.p.) was significantly greater than that observed in saline‐treated rats. The yawning behaviour, however, was not dose‐dependent nor was the number of yawns in any of the drug treated groups significantly greater than in those treated with saline.
Pretreatment (30 min) with the non‐selective muscarinic antagonists scopolamine (0.1, 0.3 or 1 mg kg−1, i.p.) and atropine (0.3, 1 or 3 mg kg−1, s.c.) but not methylatropine (1, 3 or 10 mg kg−1, s.c) significantly inhibited stretching induced by Ro 04–6790 (30 mg kg−1, i.p.).
The dopamine D2‐like receptor antagonist, haloperidol (0.03, 0.1 or 0.3 mg kg−1, s.c.) given at the same time as Ro 04–6790 (30 mg kg−1, i.p.) had no effect on the stretching induced by the 5‐HT6 antagonist.
These data suggest that systemic injection of the 5‐HT6 antagonist, Ro 04–6790, produces a stretching behaviour that appears to be mediated by an increase in cholinergic neurotransmission in the CNS and which could be a useful functional correlate for 5‐HT6 receptor blockade. There is no evidence for dopamine D2‐like receptor involvement in this behaviour.
British Journal of Pharmacology (1999) 126, 1537–1542; doi:10.1038/sj.bjp.0702445</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1038/sj.bjp.0702445</identifier><identifier>PMID: 10323584</identifier><identifier>CODEN: BJPCBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>4‐amino‐N‐(2,6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide ; 5‐HT6 ; Acetylcholine - secretion ; Animals ; Atropine - pharmacology ; Atropine Derivatives - pharmacology ; Behavior, Animal - drug effects ; behaviour ; Biological and medical sciences ; chewing ; locomotor activity ; Male ; Medical sciences ; Motor Activity - drug effects ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Oligonucleotides, Antisense - pharmacology ; Pharmacology. Drug treatments ; Pyrimidines - pharmacology ; Rats ; Rats, Sprague-Dawley ; Receptors, Serotonin - drug effects ; Ro 04–6790 ; Scopolamine Hydrobromide - pharmacology ; Serotonin Antagonists - pharmacology ; Serotoninergic system ; stretching ; yawning ; Yawning - drug effects</subject><ispartof>British journal of pharmacology, 1999-04, Vol.126 (7), p.1537-1542</ispartof><rights>1999 Nature Publishing Group</rights><rights>1999 INIST-CNRS</rights><rights>Copyright 1999, Nature Publishing Group 1999 Nature Publishing Group</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1565929/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1565929/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1759747$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10323584$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bentley, Jane C</creatorcontrib><creatorcontrib>Bourson, Anne</creatorcontrib><creatorcontrib>Boess, Frank G</creatorcontrib><creatorcontrib>Fone, Kevin C F</creatorcontrib><creatorcontrib>Marsden, Charles A</creatorcontrib><creatorcontrib>Petit, Nadine</creatorcontrib><creatorcontrib>Sleight, Andrew J</creatorcontrib><title>Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>The present study examined the effects of the selective 5‐HT6 receptor antagonist 4‐amino‐N‐(2, 6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide (Ro 04–6790) on locomotor activity and unconditioned behaviour in male Sprague Dawley rats (230–300 g).
In non‐quantified behavioural observations, animals treated with Ro 04–6790 (3, 10 or 30 mg kg−1, i.p) showed no overt behavioural signs except a dose‐dependent reduction in locomotor activity and a behavioural syndrome of stretching, yawning and chewing. The latter behaviour was most pronounced between 30 and 90 min following the administration of Ro 04–6790.
Detailed analysis of the stretching and yawning behaviour showed that Ro 04–6790 (3, 10 or 30 mg kg−1, i.p.) dose‐dependently induced stretching. The number of stretches observed following treatment with either Ro 04–6790 (10 mg kg−1 i.p.) or Ro‐04‐6790 (30 mg kg−1, i.p.) was significantly greater than that observed in saline‐treated rats. The yawning behaviour, however, was not dose‐dependent nor was the number of yawns in any of the drug treated groups significantly greater than in those treated with saline.
Pretreatment (30 min) with the non‐selective muscarinic antagonists scopolamine (0.1, 0.3 or 1 mg kg−1, i.p.) and atropine (0.3, 1 or 3 mg kg−1, s.c.) but not methylatropine (1, 3 or 10 mg kg−1, s.c) significantly inhibited stretching induced by Ro 04–6790 (30 mg kg−1, i.p.).
The dopamine D2‐like receptor antagonist, haloperidol (0.03, 0.1 or 0.3 mg kg−1, s.c.) given at the same time as Ro 04–6790 (30 mg kg−1, i.p.) had no effect on the stretching induced by the 5‐HT6 antagonist.
These data suggest that systemic injection of the 5‐HT6 antagonist, Ro 04–6790, produces a stretching behaviour that appears to be mediated by an increase in cholinergic neurotransmission in the CNS and which could be a useful functional correlate for 5‐HT6 receptor blockade. There is no evidence for dopamine D2‐like receptor involvement in this behaviour.
British Journal of Pharmacology (1999) 126, 1537–1542; doi:10.1038/sj.bjp.0702445</description><subject>4‐amino‐N‐(2,6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide</subject><subject>5‐HT6</subject><subject>Acetylcholine - secretion</subject><subject>Animals</subject><subject>Atropine - pharmacology</subject><subject>Atropine Derivatives - pharmacology</subject><subject>Behavior, Animal - drug effects</subject><subject>behaviour</subject><subject>Biological and medical sciences</subject><subject>chewing</subject><subject>locomotor activity</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Motor Activity - drug effects</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Oligonucleotides, Antisense - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrimidines - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Serotonin - drug effects</subject><subject>Ro 04–6790</subject><subject>Scopolamine Hydrobromide - pharmacology</subject><subject>Serotonin Antagonists - pharmacology</subject><subject>Serotoninergic system</subject><subject>stretching</subject><subject>yawning</subject><subject>Yawning - drug effects</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkcFOGzEQhq2KqqS01x4rHxAnEuy1vd69IBVUGiQkqip3y-udTRxt7MX2psqNR0DiDXkSXJG2cJrDfPPN6B-EvlAyo4RVZ3E9a9bDjEhScC7eoQnlspwKVtEDNCGEyCmlVXWIPsa4JiQ3pfiADvNowUTFJ-ju2m0hJrvUyXqHfYdjCpDMyrolbmClt9aPAVvXjgZa3OxwWgGO0INJdgtYPN0_zBclDmBgSD5g7ZJeemdjOsW_PCb86f6xlDU5zQ4cdIqf0PtO9xE-7-sRWlx9X1zOpze3P64vv91MByYFy2eTspWGM1owDm3ZVVQXdUsK0zQ1rSQ1gpkOjK47yaUoiaGmZaTQLWdgOnaEzl-0w9hsoDXgUtC9GoLd6LBTXlv1tuPsSi39VlFRirqos-BkLwj-bswZqY2NBvpeO_BjVGUtOc-5Z_Dr603_VvwNOQPHe0BHo_suaGds_M9JkVUyY-wF-2172L3S_DFVKq5V_rTaf1pd_JxTIhl7BkFdnsI</recordid><startdate>199904</startdate><enddate>199904</enddate><creator>Bentley, Jane C</creator><creator>Bourson, Anne</creator><creator>Boess, Frank G</creator><creator>Fone, Kevin C F</creator><creator>Marsden, Charles A</creator><creator>Petit, Nadine</creator><creator>Sleight, Andrew J</creator><general>Blackwell Publishing Ltd</general><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>199904</creationdate><title>Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats</title><author>Bentley, Jane C ; Bourson, Anne ; Boess, Frank G ; Fone, Kevin C F ; Marsden, Charles A ; Petit, Nadine ; Sleight, Andrew J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p3753-1106d7c431234ed6f81a29d02cbb91871c53cfeca9f747560c1cd302ad43ecf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>4‐amino‐N‐(2,6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide</topic><topic>5‐HT6</topic><topic>Acetylcholine - secretion</topic><topic>Animals</topic><topic>Atropine - pharmacology</topic><topic>Atropine Derivatives - pharmacology</topic><topic>Behavior, Animal - drug effects</topic><topic>behaviour</topic><topic>Biological and medical sciences</topic><topic>chewing</topic><topic>locomotor activity</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Motor Activity - drug effects</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Oligonucleotides, Antisense - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrimidines - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Serotonin - drug effects</topic><topic>Ro 04–6790</topic><topic>Scopolamine Hydrobromide - pharmacology</topic><topic>Serotonin Antagonists - pharmacology</topic><topic>Serotoninergic system</topic><topic>stretching</topic><topic>yawning</topic><topic>Yawning - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bentley, Jane C</creatorcontrib><creatorcontrib>Bourson, Anne</creatorcontrib><creatorcontrib>Boess, Frank G</creatorcontrib><creatorcontrib>Fone, Kevin C F</creatorcontrib><creatorcontrib>Marsden, Charles A</creatorcontrib><creatorcontrib>Petit, Nadine</creatorcontrib><creatorcontrib>Sleight, Andrew J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bentley, Jane C</au><au>Bourson, Anne</au><au>Boess, Frank G</au><au>Fone, Kevin C F</au><au>Marsden, Charles A</au><au>Petit, Nadine</au><au>Sleight, Andrew J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>1999-04</date><risdate>1999</risdate><volume>126</volume><issue>7</issue><spage>1537</spage><epage>1542</epage><pages>1537-1542</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><coden>BJPCBM</coden><abstract>The present study examined the effects of the selective 5‐HT6 receptor antagonist 4‐amino‐N‐(2, 6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide (Ro 04–6790) on locomotor activity and unconditioned behaviour in male Sprague Dawley rats (230–300 g).
In non‐quantified behavioural observations, animals treated with Ro 04–6790 (3, 10 or 30 mg kg−1, i.p) showed no overt behavioural signs except a dose‐dependent reduction in locomotor activity and a behavioural syndrome of stretching, yawning and chewing. The latter behaviour was most pronounced between 30 and 90 min following the administration of Ro 04–6790.
Detailed analysis of the stretching and yawning behaviour showed that Ro 04–6790 (3, 10 or 30 mg kg−1, i.p.) dose‐dependently induced stretching. The number of stretches observed following treatment with either Ro 04–6790 (10 mg kg−1 i.p.) or Ro‐04‐6790 (30 mg kg−1, i.p.) was significantly greater than that observed in saline‐treated rats. The yawning behaviour, however, was not dose‐dependent nor was the number of yawns in any of the drug treated groups significantly greater than in those treated with saline.
Pretreatment (30 min) with the non‐selective muscarinic antagonists scopolamine (0.1, 0.3 or 1 mg kg−1, i.p.) and atropine (0.3, 1 or 3 mg kg−1, s.c.) but not methylatropine (1, 3 or 10 mg kg−1, s.c) significantly inhibited stretching induced by Ro 04–6790 (30 mg kg−1, i.p.).
The dopamine D2‐like receptor antagonist, haloperidol (0.03, 0.1 or 0.3 mg kg−1, s.c.) given at the same time as Ro 04–6790 (30 mg kg−1, i.p.) had no effect on the stretching induced by the 5‐HT6 antagonist.
These data suggest that systemic injection of the 5‐HT6 antagonist, Ro 04–6790, produces a stretching behaviour that appears to be mediated by an increase in cholinergic neurotransmission in the CNS and which could be a useful functional correlate for 5‐HT6 receptor blockade. There is no evidence for dopamine D2‐like receptor involvement in this behaviour.
British Journal of Pharmacology (1999) 126, 1537–1542; doi:10.1038/sj.bjp.0702445</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>10323584</pmid><doi>10.1038/sj.bjp.0702445</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 1999-04, Vol.126 (7), p.1537-1542 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1565929 |
| source | MEDLINE; Wiley Free Content; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | 4‐amino‐N‐(2,6 bis‐methylamino‐pyrimidin‐4‐yl)‐benzene sulphonamide 5‐HT6 Acetylcholine - secretion Animals Atropine - pharmacology Atropine Derivatives - pharmacology Behavior, Animal - drug effects behaviour Biological and medical sciences chewing locomotor activity Male Medical sciences Motor Activity - drug effects Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Oligonucleotides, Antisense - pharmacology Pharmacology. Drug treatments Pyrimidines - pharmacology Rats Rats, Sprague-Dawley Receptors, Serotonin - drug effects Ro 04–6790 Scopolamine Hydrobromide - pharmacology Serotonin Antagonists - pharmacology Serotoninergic system stretching yawning Yawning - drug effects |
| title | Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T00%3A26%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigation%20of%20stretching%20behaviour%20induced%20by%20the%20selective%205%E2%80%90HT6%20receptor%20antagonist,%20Ro%2004%E2%80%936790,%20in%20rats&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Bentley,%20Jane%20C&rft.date=1999-04&rft.volume=126&rft.issue=7&rft.spage=1537&rft.epage=1542&rft.pages=1537-1542&rft.issn=0007-1188&rft.eissn=1476-5381&rft.coden=BJPCBM&rft_id=info:doi/10.1038/sj.bjp.0702445&rft_dat=%3Cproquest_pubme%3E69744070%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69744070&rft_id=info:pmid/10323584&rfr_iscdi=true |